Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE0005664809
Mon, 03.01.2022
Evotec SE
EVOTEC RECEIVES A € 7.5 M GRANT FROM THE GERMAN FEDERAL MINISTRY OF EDUCATION AND RESEARCH ("BMBF") FOR THE DEVELOPMENT OF A THERAPEUTIC AGAINST COVID-19
EVOTEC IS DEVELOPING A HIGHLY POTENT IMMUNOMODULATORY MOLECULE THAT HOLDS THE POTENTIAL TO AMPLIFY THE IMMUNE RESPONSE AND REDUCE THE RISK OF DIFFICULT DISEASE PROGRESSION AND HOSPITALISATION
Ham [ … ]
Thu, 16.12.2021
Evotec SE
GRANT WILL SUPPORT FULLY INTEGRATED DRUG DISCOVERY PROGRAMME FROM SCREENING TO PRE-CLINICAL DEVELOPMENT CANDIDATE
PROJECT LEVERAGES EVOTEC'S WOMEN'S HEALTH PLATFORM AND AI/ML MOLECULAR DESIGN TOOLS
Hamburg, Germany, 16 December 2021:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that the Co [ … ]
Thu, 18.11.2021
Evotec SE
EQRX TO LEVERAGE EVOTEC'S UNIQUE DATA-DRIVEN INTEGRATED DRUG DISCOVERY AND DEVELOPMENT ACCELERATOR PLATFORM
PARTNERSHIP AIMS TO BUILD UP JOINTLY OWNED PIPELINE TO DELIVER INNOVATIVE, AFFORDABLE AND ACCESSIBLE MEDICINES TO PATIENTS
Hamburg, Germany, and Cambridge, Mass., USA, 18 November 2021:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDA [ … ]
Thu, 11.11.2021
Evotec SE
STRONG OPERATIONAL PERFORMANCE LEADS TO SIGNIFICANT REVENUE GROWTH
CO-OWNED PIPELINE GAINING MOMENTUM
J.POD(R) REDMOND (US) OPERATIONAL
SUCCESSFUL PUBLIC OFFERING AT NASDAQ (AFTER PERIOD-END)
GUIDANCE FOR FULL-YEAR 2021 CONFIRMED
WEBCAST AND CONFERENCE CALL TODAY AT 02.00 PM CET
Hamburg, Germany, 11 November 2021:
Evotec SE (Frankfurt Stock [ … ]
Wed, 10.11.2021
Evotec SE
THE DESIGNATION OF ADDITIONAL PROGRAMMES BY BRISTOL MYERS SQUIBB TRIGGERED PAYMENTS OF IN TOTAL US$ 40 M TO EVOTEC
Hamburg, Germany, 10 November 2021:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809, NASDAQ: EVO) announced today that the Company reached additional programme designations within its neuroscience collaboratio [ … ]
Tue, 09.11.2021
Evotec SE
Hamburg, Germany, 09 November 2021:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today the closing of its public offering on 08 November 2021 in the United States of 20,000,000 American Depositary Shares ("ADSs"). Each ADS represents half of one ordinary share of Evotec. All ADSs sold in the offe [ … ]
Wed, 03.11.2021
Evotec SE
Hamburg, Germany, 03 November 2021:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) will announce its financial results for the first nine months 2021 on Thursday, 11 November 2021.
The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. The conference [ … ]
Tue, 26.10.2021
Evotec SE
Hamburg, Germany, 26 October 2021:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that it has commenced a public offering in the United States of up to 22,000,000 American Depositary Shares ("ADSs") representing 11,000,000 of its ordinary shares pursuant to a registration statement on Form F-1, as amended [ … ]
Tue, 26.10.2021
Evotec SE
9M 2021 REVENUES EXPECTED TO BE IN THE RANGE OF € 425 - 435 M
ADJUSTED 9M 2021 EBITDA EXPECTED TO BE IN THE RANGE OF € 68 - 72 M
THE FIGURES IN THIS ANNOUNCEMENT ARE PRELIMINARY AND SUBJECT TO CHANGE
THE COMPLETE 9M 2021 INTERIM FINANCIAL RESULTS WILL BE RELEASED AS SCHEDULED ON 11 NOVEMBER 2021
Hamburg, Germany, 26 October 2021:
Evotec SE (Fran [ … ]
Mon, 11.10.2021
Evotec SE
Hamburg, Germany, 11 October 2021:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission ("SEC") relating to a proposed offering and sale in the United States of shares of Evotec represented by American Deposi [ … ]